Niagen Bioscience (NAGE) Receivables - Other (2013 - 2026)

Niagen Bioscience (NAGE) has 12 years of Receivables - Other data on file, last reported at $3.4 million in Q1 2026.

• On a quarterly basis, Receivables - Other rose 267.5% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 386.87% increase from a year earlier, with the FY2025 full-year figure at $756000.0, down 40.89% from the prior year.
• Receivables - Other for Q1 2026 stood at $3.4 million, up from $1.3 million in the prior quarter.
• Over the last five years, Receivables - Other for NAGE reached as high as $3.8 million in Q4 2022 and fell as low as -$2.7 million in Q2 2023.
• Historically, Receivables - Other has averaged $904764.7 across 5 years, with a median of $1.3 million in 2025.
• Across the five-year window, Receivables - Other soared 2802.31% in 2022 and tumbled 305.23% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $3.8 million in 2022, then slumped by 109.22% to -$348000.0 in 2023, then slumped by 84.48% to -$642000.0 in 2024, then jumped by 296.57% to $1.3 million in 2025, then soared by 170.36% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.4 million in Q1 2026, $1.3 million in Q4 2025, and -$1.2 million in Q3 2025.